Notably, these studies fall into the same category as the overwhelming number of preclinical and clinical studies to date that have investigated the ability of combination regimens incorporating to PD-1/PD-L1/CTLA-4 inhibitors to target primary resistance or improve response to checkpoint blockade in pancreatic cancer (Tables 1 and 2). Here, CTLA4 is linked to pancreatic neoplasm.